Company profile
Biofrontera Inc.
NASDAQ: BFRI · Healthcare · Medical - Pharmaceuticals
#458 of 1,418 Healthcare companies by revenue57th-percentile growth
EA Score
46DFH 46DQ 34GM 69SS 42
v0.1 · 65/100 weight · provisional
↑ growth stability, net margin · ↓ listing tenure, Piotroski F
Methodology →Revenue TTM
$43.2M
Rev growth YoY (TTM)
+13.7%
Net income (FY)
-$10.5M
Employees
89
as of 2026-08-22
Market cap
$18.9M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$41.7M$41.7M2025
Net income-$10.5M-$10.5M2025
Operating income-$11.3M-$11.3M2025
Total assets$28.6M$28.6M2025
Liabilities$18.1M$18.1M2025
Equity$10.5M$10.5M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2023
By product
Government and Payor Rebates58%
Co-pay Assistance Program31%
Returns10%
Prompt Pay Discounts1%
By geography
Not disclosed.
The read
What is Biofrontera Inc.’s revenue?
Biofrontera Inc. booked $41.7M in FY2025 revenue, growing 12% year over year — about the middle of the pack among Healthcare companies we track, at a -25.3% net margin.
Peers · Healthcare
Rubicon Organics Inc.63CSS Innovations International, Inc.53DCoherus Oncology, Inc.61CSelectis Health, Inc.60CKORU Medical Systems, Inc.72BFilana Therapeutics, Inc.42DNeighbors
Middlesex →Key facts
CEOHermann Lübbert
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersWoburn, MA
ExchangeNASDAQ: BFRI
Employees89
IPO date2021-10-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.